A phase I study of bi-weekly administration of 24-hr gemcitabine (GEM) followed by 24-hr irinotecan (CPT-11) in patients with solid tumors No significant financial relationships to disclose. This is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback